What Pharmaterials does

Pharmaterials is a contract development and manufacturing organization (CDMO) headquartered in Reading, United Kingdom, founded in 2000 and operating with 51-100 employees. The firm's website is pharmaterials.co.uk. Based on the firmographic record, Pharmaterials occupies the small-cap segment of the UK pharmaceutical services market, offering formulation development, clinical manufacturing, and related drug product services to pharmaceutical and biotech clients across the development lifecycle.

The supporting structured intelligence in this dataset, however, is principally attributed to Quotient Sciences — a Nottingham-area CRDMO (Contract Research, Development and Manufacturing Organization) operating across the UK and US, with a service portfolio covering Drug Product Development & Manufacturing, Early Clinical Development (first-in-human and clinical pharmacology), Translational Pharmaceutics® integrated drug development, and Pediatric Formulation Development. Quotient Sciences markets itself as a CRDMO with a registered trademark in Translational Pharmaceutics® and a direct enterprise sales motion targeting pharma and biotech accounts. Whether Pharmaterials and Quotient Sciences are the same operating entity under different trading names, related entities, or distinct firms whose data has been conflated in the source scrape is not resolved by the available evidence. This analysis treats Pharmaterials strictly on the basis of its confirmed firmographic record and flags the data provenance issue as a material limitation.

On the firmographic record alone, Pharmaterials is positioned as a long-tenured, sub-100-employee UK CDMO serving pharmaceutical and biotech customers with development and manufacturing services, with no disclosed revenue, funding, ownership, or leadership data available in the source material.

Name

Pharmaterials

Legal name

Quotient Sciences

Website

https://pharmaterials.co.uk

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Pharmaterials is a Reading, UK-based contract development and manufacturing organization (CDMO) founded in 2000, employing 51-100 staff to deliver formulation development and pharmaceutical manufacturing services to pharma and biotech clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing Services (CDMO/CRDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical drug development
• Contract manufacturing services
• Formulation development
• Clinical pharmacology trials
• Commercial drug manufacturing

Headquarters

HQ city

Reading

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Research and Development Services: Service-based revenue model providing integrated pharmaceutical development services including formulation development, clinical manufacturing, and early clinical development programs. Revenue is generated through project-based contracts with pharmaceutical and biotech companies across various development stages.
2. Drug Product Manufacturing: cGMP manufacturing services for clinical trial materials and commercial drug product supply, generating recurring revenue from ongoing manufacturing relationships with clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Pharmaterials is a pharmaceutical contract development and manufacturing organization (CDMO/CRDMO) providing integrated drug development and manufacturing services to pharmaceutical and biotech companies. The company offers formulation development, cGMP clinical and commercial drug product manufacturing, early clinical development programs (including first-in-human and Phase 1 clinical pharmacology), the proprietary Translational Pharmaceutics® approach, and pediatric formulation development, taking client molecules from candidate selection through to commercial drug supply.

Product overview

Quotient Sciences operates as a pharmaceutical CRDMO (Contract Research, Development and Manufacturing Organization) offering an integrated portfolio of drug development services. The company provides four core service offerings: Drug Product Development & Manufacturing (covering formulation development, clinical manufacturing, and commercial production), Early Clinical Development (first-in-human and clinical pharmacology programs), Translational Pharmaceutics® Integrated Drug Development (which uniquely combines clinical activities with real-time cGMP manufacturing), and Pediatric Formulation Development. These services are designed to take molecules from candidate selection through first-in-human clinical testing to commercial supply, with an emphasis on accelerating timelines.

Differentiator

Problem solved

Functional benefit

Brands

• Translational Pharmaceutics: The company's unique approach to drug development, integrating clinical activities with real-time cGMP drug product manufacturing

Products and services

• Drug Product Development & Manufacturing Experienced formulation development, clinical manufacturing, and sustained commercial production of pharmaceutical products, delivered to pharmaceutical and biotech companies developing small molecule drugs.
• Early Clinical Development Integrated first-in-human and clinical pharmacology programs designed to help pharmaceutical and biotech companies make critical go/no-go decisions earlier in drug development; includes Phase I clinical pharmacology, regulatory, and labeling studies.
• Translational Pharmaceutics® Integrated Drug Development Unique, proprietary approach to drug development that integrates clinical activities with real-time cGMP drug product manufacturing, enabling adaptive clinical program decisions and accelerated development timelines for pharmaceutical and biotech clients.
• Pediatric Formulation Development Specialized solutions for developing age-appropriate drug formulations for pediatric populations, serving pharmaceutical and biotech companies needing tailored pediatric dosage forms.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves2 records

Expansion highlights2 records

Broad incumbents

• Recipharm: European-headquartered CDMO offering formulation development, clinical and commercial manufacturing across multiple dosage forms. Comparable as a mid-to-large CDMO serving pharma sponsors across the small-molecule development lifecycle.
• PCI Pharma Services: Global CDMO offering clinical trial material manufacturing, commercial supply, and formulation development. Comparable in providing GMP manufacturing and clinical supply services to pharma sponsors.
• Aenova Group: European CDMO offering solid dose, semi-solid, and sterile manufacturing plus formulation development. Comparable to Pharmaterials as a CDMO providing small-molecule drug product development and clinical supply services.
• Cambrex: Small-molecule API and drug product CDMO offering formulation development, clinical and commercial manufacturing. Directly comparable in the small-molecule CDMO space with overlapping service portfolio targeting pharma and biotech sponsors.
• Piramal Pharma Solutions: Global CDMO providing drug substance and drug product services including formulation development and clinical manufacturing. Comparable as a contract development and manufacturing partner for small-molecule programs.
• AMRI (Curia): Global CDMO offering API, drug product, and formulation development plus clinical and commercial manufacturing. Comparable as a broad CDMO serving pharma and biotech across the development lifecycle.

Direct peers

• Quotient Sciences: Parent/affiliated CRDMO with operations in the UK and US that pioneered Translational Pharmaceutics®. Directly comparable as a small-molecule drug product CDMO offering formulation, clinical manufacturing, and integrated development services to pharma and biotech sponsors.
• APC (Ardena): European CDMO offering small-molecule drug substance, drug product, and formulation development including GMP clinical manufacturing. Highly comparable as a mid-sized specialist focused on small-molecule CDMO services.
• Dottikon ES: Swiss-based specialty CDMO focused on hazardous small-molecule API and drug product development. Comparable as a mid-sized specialist CDMO offering formulation and GMP manufacturing for pharma sponsors.

Emerging players

• Sai Life Sciences: India-headquartered CDMO providing drug substance, drug product, and formulation development services. Comparable as a mid-sized emerging CDMO competing in the small-molecule development and manufacturing space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaterials